Aldeyra Therapeutics, Inc. (NasdaqCM: ALDX)
Health Care · Biotechnology · US
$0.70
-23.59% today · -87.1% 1Y
Aldeyra Therapeutics, Inc. (NasdaqCM: ALDX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $42.23M and employs 6 people.
Over the last twelve months the share price has lost 87.1%, trading between 0.65 and 5.93.
Tweenvest scores Aldeyra Therapeutics, Inc. across four factors: quality 35/100, value 25/100. Its strongest factor is quality.
ALDX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $42.23M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.38
- Dividend yield
- —
- Beta (5Y)
- 1.20
- 52-week high
- $5.93
- 52-week low
- $0.65
- Avg volume (3M)
- —
- Shares outstanding
- 60.33M
- Employees
- 6
- Next earnings
- —
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
- ISIN
- US01438T1060
- Founded
- 2004
- Listed since
- May 2, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Psomagen, Inc.KOSDAQ: A950200 | $42.85M | ₩2,970.00 | -0.17% |
| INmune Bio Inc.NasdaqCM: INMB | $42.46M | $1.53 | -4.97% |
| Biomea Fusion, Inc.NasdaqGS: BMEA | $42.40M | $0.59 | -15.23% |
| Annovis Bio, Inc.NYSE: ANVS | $42.32M | $0.99 | -17.90% |
| Dogwood Therapeutics, Inc.NasdaqCM: DWTX | $41.47M | $1.22 | -12.86% |
| Biomolecular Life Holdings, Inc.OTCPK: BIOM | $41.44M | $0.81 | -18.18% |
| KoBioLabs, IncKOSDAQ: A348150 | $40.93M | ₩2,810.00 | -2.43% |
| Cutia TherapeuticsSEHK: 2487 | $40.89M | HK$0.86 | +0.58% |
Figures last refreshed Oct 18, 2026.